Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.

• Authors: Michael Asger Andersen, Rebecca Valentin, Lene Dissing Sjö, Line Borgwardt, Kjeld Schmiegelow, Mette Klarskov Andersen, Rasmus L Marvig, Christina Westmose Yde, Carsten Utoft Niemann
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 59 Issue 12 Pg. 1547-1551 (Dec 2020) ISSN: 1651-226X [Electronic] England
• PMID: 32970500 (Publication Type: Case Reports, Letter)

Chemical References

• Bridged Bicyclo Compounds, Heterocyclic
• Sulfonamides
• Alemtuzumab
• venetoclax

Topics

• Adult
• Alemtuzumab (therapeutic use)
• Bridged Bicyclo Compounds, Heterocyclic
• Epigenesis, Genetic
• Humans
• Leukemia, Prolymphocytic
• Leukemia, Prolymphocytic, T-Cell (genetics)
• Lymphoma
• Male
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Sulfonamides
• T-Lymphocytes